Regeneron Pharmaceuticals Stock Filter Stocks by Fundamentals
| REGN Stock | USD 893.99 7.20 0.80% |
Regeneron Pharmaceuticals fundamentals help investors to digest information that contributes to Regeneron Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Regeneron Stock. The fundamental analysis module provides a way to measure Regeneron Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regeneron Pharmaceuticals stock.
Regeneron | Shares Owned by Institutions |
Regeneron Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Regeneron Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Regeneron Pharmaceuticals' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Regeneron Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Regeneron Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Regeneron Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Regeneron Pharmaceuticals' value.| Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.1 M | Wellington Management Company Llp | 2023-12-31 | 1.1 M | Norges Bank | 2023-12-31 | 1.1 M | Northern Trust Corp | 2023-12-31 | 1 M | Legal & General Group Plc | 2023-12-31 | 985.5 K | Bank Of New York Mellon Corp | 2023-12-31 | 948.6 K | American Century Companies Inc | 2023-12-31 | 931.3 K | Amundi | 2023-12-31 | 914.1 K | Bank Of America Corp | 2023-12-31 | 878.4 K | Fmr Inc | 2023-12-31 | 10.3 M | Vanguard Group Inc | 2023-12-31 | 8.8 M |
Regeneron Fundamentals
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0849 | ||||
| Profit Margin | 0.30 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 88.03 B | ||||
| Shares Outstanding | 107.94 M | ||||
| Shares Owned By Insiders | 2.58 % | ||||
| Shares Owned By Institutions | 89.27 % | ||||
| Number Of Shares Shorted | 1.42 M | ||||
| Price To Earning | 15.51 X | ||||
| Price To Book | 3.82 X | ||||
| Price To Sales | 7.57 X | ||||
| Revenue | 13.12 B | ||||
| Gross Profit | 7.02 B | ||||
| EBITDA | 4.05 B | ||||
| Net Income | 3.95 B | ||||
| Cash And Equivalents | 7.02 B | ||||
| Cash Per Share | 65.75 X | ||||
| Total Debt | 2.7 B | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.36 X | ||||
| Book Value Per Share | 242.47 X | ||||
| Cash Flow From Operations | 4.59 B | ||||
| Short Ratio | 3.19 X | ||||
| Earnings Per Share | 34.78 X | ||||
| Price To Earnings To Growth | 1.46 X | ||||
| Target Price | 1048.33 | ||||
| Number Of Employees | 13.45 K | ||||
| Beta | 0.14 | ||||
| Market Capitalization | 98.14 B | ||||
| Total Asset | 33.08 B | ||||
| Retained Earnings | 27.26 B | ||||
| Working Capital | 16.06 B | ||||
| Current Asset | 2.92 B | ||||
| Current Liabilities | 811.16 M | ||||
| Net Asset | 33.08 B |
About Regeneron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regeneron Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regeneron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regeneron Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Regeneron Pharmaceuticals Piotroski F Score and Regeneron Pharmaceuticals Altman Z Score analysis. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.78 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.